- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
The Il Effects of Asthma
17 December 1998 6:00 pm
An asthma attack is nothing to sneeze at. In a dramatic--and dangerous--overreaction by the immune system, the lungs pump out mucus and inflammatory molecules, clogging and swelling constricted airways. In tomorrow's Science, two independent teams present evidence that an immune system messenger called interleukin-13 (IL-13) may be a key culprit in such attacks. The results come from mouse studies, but if they hold up in humans, they suggest two promising targets for antiasthma therapies.
Although IL-13 was known to play a role in asthma, until now it was difficult to distinguish its contribution from that of its sibling molecule, interleukin-4. But a new molecule that selectively mops up IL-13 from airways has allowed the two teams of scientists to clarify the mischief of these twin messengers--and suggests that IL-13 deserves a greater share of blame in attacks.
The new molecule binds to IL-13, preventing it from attaching to its receptors on immune system cells. In independent work, teams led by immunologist Marsha Wills-Karp of Johns Hopkins University and David Corry of the University of California, San Francisco, both found that the IL-13 blocker lessened the signs of asthma in mice. In addition, Corry's team tested IL-13 and IL-4 themselves by applying a drop of one or the other directly in the mice's nasal passages. The mice that received IL-13 appeared to develop worse asthma symptoms. "While IL-4 plays a role," Corry says, "IL-13 may be more potent."
A promising drug target, say several scientists, is the portion of the receptor molecule on immune system cells that is shared by both IL-4 and IL-13. Several companies are already seeking an effective way to block the receptor's signaling. The interleukin molecules "won't give you asthma without that receptor," Corry says. "That kind of bottleneck is the perfect target for designing new therapies."